About
Glenn Markov is a biotech founder and operator focused on longevity therapeutics. He is the co-founder and COO of Rejuvenation Technologies, which is developing mRNA-based therapies targeting telomere shortening and age-related disease. Y Combinator lists him as a Stanford PhD in Genetics, and company materials tie his work to telomere extension and epigenetic reprogramming research done in Helen Blau's lab.
Areas of interest
longevitybiotechmRNA therapeuticsgene therapytelomere biologyepigenetic reprogrammingnanomedicineage-related disease therapeutics